Multiparametric Imaging in Multiple Myeloma

• Status: Completed
• Trial end date: 2021-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography imaging with intravenously injected C11 Methionine to detect viable lesions.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yingbing Wang
• Treatments: Carbon-11 methionine

Criteria

Inclusion Criteria:

• Diagnosis of Multiple Myeloma with symptomatic bone or soft tissue disease

• Eastern Cooperative Oncology Group status 0 to 2

• Life expectance >= 12 weeks

• Ability to understand and willingness to sign informed consent

• Tissue sampling with genotype data planned within 3 months of C11 positron emission tomography (PET) imaging

Exclusion Criteria:

• Pregnant or breast feeding

• Claustrophobic reactions and unable to lie still on a bed inside the PET scanner for 60 minutes

• Research related radiation exposure exceeding 50 millisieverts